TY  - GEN
AU  - Piccart,M J
AU  - Di Leo,A
AU  - Beauduin,M
AU  - Vindevoghel,A
AU  - Michel,J
AU  - Focan,C
AU  - Tagnon,A
AU  - Ries,F
AU  - Gobert,P
AU  - Finet,C
AU  - Closon-Dejardin,M T
AU  - Dufrane,J P
AU  - Kerger,J
AU  - Liebens,F
AU  - Beauvois,S
AU  - Bartholomeus,S
AU  - Dolci,S
AU  - Lobelle,J P
AU  - Paesmans,M
AU  - Nogaret,J M
TI  - Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer
SN  - 0732-183X
PY  - 2001///0705
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Belgium
KW  - epidemiology
KW  - Breast Neoplasms
KW  - drug therapy
KW  - Chemotherapy, Adjuvant
KW  - methods
KW  - Cyclophosphamide
KW  - administration & dosage
KW  - Disease-Free Survival
KW  - Dose-Response Relationship, Drug
KW  - Epirubicin
KW  - Female
KW  - Fluorouracil
KW  - Humans
KW  - Methotrexate
KW  - Middle Aged
KW  - Prognosis
KW  - Proportional Hazards Models
KW  - Statistics, Nonparametric
KW  - Survival Rate
N1  - Publication Type: Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
UR  - https://doi.org/10.1200/JCO.2001.19.12.3103
ER  -